Hemostemix Engages PatentVest to Strengthen its Global Patent Portfolio

Calgary, Alberta--(Newsfile Corp. - April 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) a leader in the development of autologous stem cell therapy for the treatment of cardiovascular diseases, announces its partnership with PatentVest.

PatentVest, a subsidiary of MDB Capital (NASDAQ: MDBH), is a premier intellectual property strategy and patent prosecution firm specializing in life sciences.

The engagement underscores Hemostemix's commitment to expanding its intellectual property portfolio to drive innovation and shareholder value. PatentVest will provide Hemostemix with a comprehensive strategic intellectual property support program, including:

1. Evaluating and optimizing Hemostemix's existing patent portfolio to ensure alignment with R&D and commercialization objectives.

2. Identifying and securing patentable claims for new therapeutic innovations.

3. Developing and executing global filing strategies to strengthen Hemostemix's IP footprint in key markets.

4. Enhancing the company's value by positioning it to attract strategic partners, expand licensing opportunities, and command premium valuations in the biotechnology sector.

"Our collaboration with PatentVest is a strategic step forward to secure additional intellectual property rights and amplify the value of our existing patents" stated Thomas Smeenk, CEO, Hemostemix. "PatentVest is accepting partial payment in equity, which aligns its incentives with the long-term success of Hemostemix shareholders. This collaboration unlocks the full potential of our innovations and maximizes our market opportunities," Smeenk said.

Will Rosellini, Chief Intellectual Property Officer of PatentVest, commented: "By applying our time-tested Leadership Development Process to build upon the Company's meaningful IP portfolio, Hemostemix will be well-positioned with a strong, defensible position in scalable autologous stem cell treatments for cardiovascular diseases. We are exploring opportunities to extend the terms of Hemostemix's patents based on its ongoing FDA studies, potentially prolonging market exclusivity for its groundbreaking therapies. Additionally, Hemostemix's license of the automated bioreactor technology promises to significantly reduce production costs, making treatments more accessible and scalable. This partnership strengthens Hemostemix's IP strategy, and positions the company to transform cardiovascular treatment affordability and drive exponential shareholder value," Rosellini added.

About PatentVest

PatentVest, a division of MDB Capital Holdings (Nasdaq: MDBH), is the first integrated IP intelligence, strategy, and law firm that enables visionary companies to develop into technology leaders. By combining our proprietary database with our proven IP diligence process and expert analysis, we deliver actionable insights on the IP landscape to help our clients make informed decisions and stay ahead of the curve. The trends and competitive insights in this report are powered by PatentVest's proprietary IP intelligence platform. Our reports keep a pulse on the key players, technologies, and opportunities shaping deep technology markets.

About Hemostemix

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in nine peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 60% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.

Stock Information: TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0 |

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: Patentvest and Hemostemix working together to generate new intellectual property and value for Hemostemix shareholders, the sale of ACP-01 as a treatment for cardiovascular diseases including vascular dementia, and the commercialization of ACP-01. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to   fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete  clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; general business, economic, competitive, political and social uncertainties; general capital market     conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and  financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression;the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. 

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/249528